US FDA granted Fast Track designation to ONIVYDE® as an investigational second-line monotherapy treatment for small cell lung cancer.
PharmaEngine and Sentinel Oncology entered into an exclusive collaboration and license agreement for SOL-578, a Chk1 inhibitor
Ipsen, PharmaEngine’s partner, presented Phase I/II clinical data evaluating Onivyde® as an investigational first-line combination treatment for metastatic pancreatic cancer at the ESMO World Congress on Gastrointestinal Cancer.
Ipsen, PharmaEngine’s partner , announced that US FDA granted Fast Track designation to ONIVYDE® as the first-line combination treatment for metastatic pancreatic cancer.
Nanobiotix, PharmaEngine’s partner, presented positive results of Phase I expansion study for PEP503 (HENSIFY ®, NBTXR3) in locally advanced head and neck cancer at ASCO 2020.
ONIVYDE® in combination with 5-fluorouracil (5-FU) and leucovorin (LV) for the treatment of metastatic adenocarcinoma of the pancreas in patients who have progressed following gemcitabine based therapy was granted the marketing authorization approval by the Ministry of Health, Labor and Welfare(MHLW), Japan.
U.S. Food and Drug Administration (FDA) granted Fast Track designation for the investigation of NBTXR3 activated by radiation therapy, with or without cetuximab, for the treatment of patients with locally advanced head and neck squamous cell cancer who are not eligible for platinum-based chemotherapy.